phrykt

Neurocrine Biosciences Inc (NBIX): who owns it and who trades it

As of Nov 16, 2026, NBIX insiders reported 50 open-market sales worth $77.4M and no purchases in the last 12 months, with 100% of the sale value made under pre-set 10b5-1 plans. The largest seller was Kevin Charles Gorman (Director), with $37.8M. 7 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Neurocrine Biosciences

From the latest filings

Overall: more buying than selling. Funds and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns NBIX

773 funds and institutions reported NBIX shares worth $17.2B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 13.6%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

BlackRock, Inc.13.6%
JPMorgan Chase & Co6.4%
Dodge & Cox5.6%
Vanguard Portfolio Management LLC4.9%
Vanguard Capital Management LLC4.5%
State Street Corp4.4%
AQR Capital Management LLC3.8%
Renaissance Technologies LLC2.3%
Geode Capital Management, LLC2.1%
Two Sigma Investments, LP2.1%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.13.71M13.64%$2.3B+2%
JPMorgan Chase & Co6.40M6.36%$1.1B–
Dodge & Cox5.58M5.55%$941M+2%
Vanguard Portfolio Management LLC4.97M4.95%$838M+5%
Vanguard Capital Management LLC4.55M4.52%$766M+1%
State Street Corp4.39M4.36%$739M+1%
AQR Capital Management LLC3.82M3.80%$643M-23%
Renaissance Technologies LLC2.34M2.32%$394M-3%
Geode Capital Management, LLC2.14M2.13%$360M+0%
Two Sigma Investments, LP2.08M2.06%$350M-32%
Vestal Point Capital, LP1.88M1.87%$317M+50%
BNP PARIBAS ASSET MANAGEMENT Holding S.A.1.49M1.49%$252MNo change
Morgan Stanley1.32M1.31%$222M+8%
Rtw Investments, LP1.27M1.26%$214M+19%
Northern Trust Corp1.26M1.25%$212M+1%
Invesco Ltd.1.08M1.07%$182M+203%
Charles Schwab Investment Management Inc974,2790.97%$164M+8%
Sixth Street Partners Management Company, L.P.974,2790.97%$164M–
Norges Bank973,8800.97%$164M–
First Trust Advisors LP923,1250.92%$156M-4%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, NBIX insiders reported $0 of open-market purchases and $77.4M of sales. 100% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$77.4M
50 trades, 14 people
Sales under a 10b5-1 plan
100%
Share of sale value
Latest trade
Nov 3, 2026
Filed Nov 3, 2026

Purchases and sales by month

$43.5M$43.5MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 3, 2026George J MorrowDirectorSale plan100$158.18$15.8KForm 4
Nov 3, 2026George J MorrowDirectorSale plan100$162.05$16.2KForm 4
Nov 3, 2026George J MorrowDirectorSale plan600$163.71$98.2KForm 4
Nov 3, 2026George J MorrowDirectorSale plan1,226$164.74$202KForm 4
Nov 3, 2026George J MorrowDirectorSale plan908$165.71$150KForm 4
Nov 3, 2026George J MorrowDirectorSale plan1,466$166.77$244KForm 4
Nov 3, 2026George J MorrowDirectorSale plan1,500$167.72$252KForm 4
Nov 3, 2026George J MorrowDirectorSale plan1,300$168.53$219KForm 4
Nov 2, 2026George J MorrowDirectorSale plan1,900$144.98$275KForm 4
Nov 2, 2026George J MorrowDirectorSale plan4,300$145.86$627KForm 4
Nov 2, 2026George J MorrowDirectorSale plan1,300$146.76$191KForm 4
Oct 30, 2026George J MorrowDirectorSale plan300$149.00$44.7KForm 4
Sep 14, 2026David W. BoyerChief Corp. Affairs OffiSale plan826$157.45$130KForm 4
Sep 14, 2026Matt AbernethyCFOSale plan2,311$157.20$363KForm 4
Sep 9, 2026Eric BenevichChief Commercial OfficerSale plan2,154$154.61$333KForm 4
Jul 28, 2026Leslie V NorwalkDirectorSale plan1,250$182.01$228KForm 4
Jul 10, 2026Ingrid DelaetChief Regulatory OfficerSale plan4,367$181.02$791KForm 4
Jul 9, 2026Darin LippoldtChief Legal OfficerSale plan10,000$179.60$1.8MForm 4
Jul 9, 2026Ingrid DelaetChief Regulatory OfficerSale plan8,433$178.72$1.5MForm 4
Jul 8, 2026Ingrid DelaetChief Regulatory OfficerSale plan2,737$178.54$489KForm 4
Jul 7, 2026Ingrid DelaetChief Regulatory OfficerSale plan3,401$178.57$607KForm 4
Jun 29, 2026Darin LippoldtChief Legal OfficerSale plan1,690$170.81$289KForm 4
Jun 29, 2026Darin LippoldtChief Legal OfficerSale plan8,110$170.03$1.4MForm 4
Jun 26, 2026Darin LippoldtChief Legal OfficerSale plan200$169.57$33.9KForm 4
Jun 5, 2026Stephen A SherwinDirectorSale plan7,883$163.81$1.3MForm 4
Jun 5, 2026Stephen A SherwinDirectorSale plan2,549$164.44$419KForm 4
Jun 5, 2026Stephen A SherwinDirectorSale plan6,896$165.79$1.1MForm 4
Jun 5, 2026Stephen A SherwinDirectorSale plan5,829$166.56$971KForm 4
Jun 5, 2026Stephen A SherwinDirectorSale plan1,843$167.31$308KForm 4
Jun 4, 2026Leslie V NorwalkDirectorSale plan1,250$168.06$210KForm 4
Jun 2, 2026Julie CookeChief Human Resources OfSale plan3,520$158.59$558KForm 4
Jun 2, 2026Julie CookeChief Human Resources OfSale plan9,521$157.62$1.5MForm 4
Jun 2, 2026Julie CookeChief Human Resources OfSale plan4,216$156.77$661KForm 4
Jun 2, 2026Julie CookeChief Human Resources OfSale plan5,466$155.46$850KForm 4
Jun 2, 2026Julie CookeChief Human Resources OfSale plan14,214$154.83$2.2MForm 4
Jun 1, 2026Jude OnyiaChief Scientific OfficerSale plan11,000$160.25$1.8MForm 4
May 29, 2026Ingrid DelaetChief Regulatory OfficerSale plan2,261$156.71$354KForm 4
May 27, 2026Jude OnyiaChief Scientific OfficerSale plan11,000$155.53$1.7MForm 4
May 26, 2026David W. BoyerChief Corp. Affairs OffiSale plan3,888$156.64$609KForm 4
May 19, 2026Kevin Charles GormanDirectorSale plan245,088$154.33$37.8MForm 4
May 15, 2026Richard F PopsDirectorSale plan15,000$157.65$2.4MForm 4
May 12, 2026Leslie V NorwalkDirectorSale plan3,810$155.01$591KForm 4
Jan 16, 2026Kyle GanoCEOSale plan1,812$132.71$240KForm 4
Jan 16, 2026Kyle GanoCEOSale plan34,588$132.70$4.6MForm 4
Dec 16, 2025Leslie V NorwalkDirectorSale plan1,190$155.09$185KForm 4
Dec 15, 2025Leslie V NorwalkDirectorSale plan5,000$152.23$761KForm 4
Dec 8, 2025Darin LippoldtChief Legal OfficerSale plan4,376$159.65$699KForm 4
Dec 3, 2025Gary A LyonsDirectorSale plan15,000$152.61$2.3MForm 4
Nov 28, 2025Eric BenevichChief Commercial OfficerSale plan5,970$151.74$906KForm 4
Nov 25, 2025George J MorrowDirectorSale plan15,000$143.37$2.2MForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Kevin Charles GormanDirector–$37.8MMay 19, 2026
Julie CookeChief Human Resources Officer–$5.8MJun 2, 2026
Kyle GanoChief Executive Officer, Director–$4.8MJan 16, 2026
George J MorrowDirector–$4.5MNov 3, 2026
Darin LippoldtChief Legal Officer–$4.2MJul 9, 2026
Stephen A SherwinDirector–$4.1MJun 5, 2026
Ingrid DelaetChief Regulatory Officer–$3.7MJul 10, 2026
Jude OnyiaChief Scientific Officer–$3.5MJun 1, 2026
Richard F PopsDirector–$2.4MMay 15, 2026
Gary A LyonsDirector–$2.3MDec 3, 2025
Leslie V NorwalkDirector–$2MJul 28, 2026
Eric BenevichChief Commercial Officer–$1.2MSep 9, 2026
David W. BoyerChief Corp. Affairs Officer–$739KSep 14, 2026
Matt AbernethyChief Financial Officer–$363KSep 14, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

NBIX short interest

Moderate short interest. 5.8% of NBIX shares are sold short: about 1 share in 17. Over the last 12 reports the number of shares short went up 14%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 5.90M NBIX shares were sold short, 5.8% of the shares outstanding, down 8.5% from the report before. At the average daily volume of 1.09M shares, buying them all back would take about 5.4 trading days (days to cover).

Shares short, % of all shares

5.83%May 15Oct 306.65%

Days to cover

5.4May 15Oct 305.8

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20265.90M5.83%-8%1.09M5.4
Oct 15, 20266.45M6.34%+10%1.42M4.5
Sep 30, 20265.85M5.76%+18%1.48M4.0
Sep 15, 20264.96M4.88%-2%924,0455.4
Aug 31, 20265.06M4.97%+11%1.09M4.7
Aug 14, 20264.55M4.48%+4%1.33M3.4
Jul 31, 20264.39M4.32%-18%1.46M3.0
Jul 15, 20265.33M5.31%-4%1.09M4.9
Jun 30, 20265.53M5.50%-3%1.32M4.2
Jun 15, 20265.69M5.66%+3%1.13M5.0
May 29, 20265.53M5.50%+7%1.11M5.0
May 15, 20265.16M5.13%-14%1.40M3.7

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Members of Congress who traded NBIX

Since Nov 17, 2024, 1 member of Congress reported 1 purchase and 1 sale of NBIX. The latest was a sale by Lisa C. McClain on Jun 17, 2025, reported Aug 13, 2025.

Purchases 1Sales 1

Reported trades

Trade dateMemberTypeAmountOwnerReportedSource
Jun 17, 2025Lisa C. McClain (R-MI)Partial sale$1K–$15KSpouseAug 13, 2025Report
Jun 11, 2025Lisa C. McClain (R-MI)Purchase$1K–$15KSpouseAug 13, 2025Report

Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work

Neurocrine Biosciences company events

Neurocrine Biosciences filed 9 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 2, 2026.

  1. Nov 2, 2026ResultsReleased financial results. Filing
  2. Sep 28, 2026LeadershipThe Board of Directors of Neurocrine Biosciences, Inc. appointed Eiry W. Roberts, M.D., to succeed Sanjay Keswani, M.D., as the Company’s Chief Medical Officer, effective September 28, 2026. Filing
  3. Jul 30, 2026ResultsReleased financial results. Filing
  4. May 28, 2026LeadershipAs discussed below in Item 5.07, Neurocrine Biosciences, Inc. held its 2026 Annual Meeting of Stockholders at which the Company’s stockholders approved an amendment of the Company’s 2025 Equity Incentive Plan. Filing
  5. May 18, 2026DealThe information set forth in the Introductory Note of this Report is incorporated by reference into this Item 2.01. Filing
  6. May 5, 2026ResultsReleased financial results. Filing
  7. Apr 6, 2026AgreementNeurocrine Biosciences, Inc., a Delaware corporation, entered into an Agreement and Plan of Merger by and among Neurocrine, Sigma Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Neurocrine, and Soleno Therapeutics, Inc., a Delaware corporation. Filing
  8. Feb 11, 2026ResultsReleased financial results. Filing
  9. Nov 24, 2025LeadershipAs previously disclosed, Sanjay Keswani, M.D. succeeded Eiry W. Roberts, M.D. as the Chief Medical Officer of Neurocrine Biosciences, Inc., effective June 2, 2025 . In connection with this transition, the Company and Dr. Roberts entered into an Amended and Restated Employment Agreement, effective… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Neurocrine Biosciences financials

Famous investors that hold NBIX

7 of the 50 well-known investors we track reported holding NBIX in their latest 13F filing. The largest position is Jim Simons's, worth $326M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 20262.30M$326M0.4%-2%
Israel Englander · Millennium ManagementQ3 2026368,839$52.3M0.0%+3084%
Ray Dalio · Bridgewater AssociatesQ3 2026206,386$29.3M0.1%+0%
Jeremy Grantham · GMOQ3 2026147,354$20.9M0.0%+103%
Ken Griffin · Citadel AdvisorsQ3 202636,382$5.2M0.0%+207%
Ken Fisher · Fisher Asset ManagementQ3 202616,467$2.3M0.0%-88%
Lee Ainslie · Maverick CapitalQ3 20263,856$547K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named NBIX in the last 120 days.

FiledHolderFormStake
Oct 30, 2026Vanguard Portfolio Management13G5.0%
Oct 30, 2026Vanguard Portfolio Management13G5.0%
Oct 15, 2026JPMORGAN CHASE & CO.13G/A5.2%
Oct 15, 2026JPMORGAN CHASE & CO.13G/A5.2%

Questions about Neurocrine Biosciences Inc (NBIX) stock

Who owns the most NBIX stock?

The largest reported owner of Neurocrine Biosciences Inc (NBIX) is BlackRock, Inc., with 13.6% of the company. In total, 773 funds and institutions reported holding NBIX at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are NBIX insiders buying or selling?

In the last 12 months, NBIX insiders reported no open-market purchases and 50 sales worth $77.4M. The latest trade was on Nov 3, 2026. See every trade.

What is the short interest in NBIX?

As of Oct 30, 2026, 5.90M NBIX shares were sold short, 5.8% of the shares outstanding, down 8.5% from the report before. At the average daily volume of 1.09M shares, buying them all back would take about 5.4 trading days (days to cover). See the history.

Have members of Congress traded NBIX?

Yes. 1 member of Congress reported 1 purchase and 1 sale of NBIX since Nov 17, 2024. The latest was reported on Aug 13, 2025. See the trades.

Which famous investors hold NBIX?

7 of the 50 well-known investors we track reported NBIX in their latest 13F filing, including Jim Simons, Israel Englander, Ray Dalio. The largest position is worth $326M. See all holders.

Executive pay

Neurocrine Biosciences's chief executive was paid a total of $6.9M for the year ended Dec 31, 2025. In the last 12 months, Neurocrine Biosciences's executives and directors bought no stock on the open market and sold $77.4M.

Chief executive, total pay$6.9MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$6MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$6.9MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.